Skip to main content

New Board Members at Millennium, Invitrogen, Exelixis, and Kinexus; Kalypsys Promotes McKearn; and Others

NEW YORK, Aug. 11 (GenomeWeb News) - Exelixis has appointed Orchid BioSciences chairman George Poste to its board of directors. Poste was formerly the president of research and development of SmithKline Beecham (now GlaxoSmithKline) and is currently director of the Biodesign Institute at Arizona State University. Poste is also CEO of the consulting company Health Technology Networks, which specializes in the application of genomic technologies and computing in healthcare. He is a member of the board of Monsanto; a fellow of the Royal Society; a William Pitt fellow of PembrokeCollege, Cambridge, UK; and a distinguished fellow at the Hoover Institution at StanfordUniversity.


Millennium Pharmaceuticals has added Charles Homcy, Raju Kucherlapati, and Eric Lander to its board as Class II directors. Homcy has served as CEO of Portola Pharmaceuticals. From January 2003 to November 2003, he was senior R&D advisor of Millennium, and was president of R&D between February 2002 and December 2002. Kucherlapati is currently scientific director of Harvard Partners Center for Genetics and Genomics. Lander is director of the Whitehead Institute's Center for Genome Research, and professor of biology at MIT.


Ronald Matricaria has joined the board of directors of Invitrogen, replacing William Mercer, who is retiring. Matricaria is the former chairman and CEO of St. Jude Medical. Before his term at St. Jude, he spent 23 years at Eli Lilly, where his last position was executive vice president of the pharmaceutical division and president of its North American operations. He also had held the position of CEO at Lilly subsidiary Cardiac Pacemakers. Matricaria also serves on the boards of directors of Cyberonics, VistaCare, and CardioDynamics, and is chairman of the board of Haemonetics.


Kinexus Bioinformatics has appointed Justin Stephenson and Joel Bellenson to its board of directors. Stephenson is the founder and president of Galiano Ventures, a Vancouver-based venture capital firm specializing in the life sciences industries.  Prior to founding Galiano Ventures in 2004, he was managing partner of the life sciences fund for RBC Capital Partners. Bellenson is currently the president and CEO of Upstream Biosciences, a Vancouver-based company developing software for modeling cell systems, protein signaling, and gene regulatory pathways. Bellenson was the co-founder and CEO of DigiScents and the co-founder, CEO, chief strategist, and director of DoubleTwist.


Kalypsys has promoted John McKearn, former chief scientific officer, to president and CSO. McKearn joined Kalypsys in July 2003 from Pharmacia, where he was senior vice president of research. Klypsys also added two new members to its board of directors, Kenneth Langone and Al Heller. Langone is the co-founder and current board member of Home Depot, and is currently the president, CEO, and chairman of Invemed Associates, an investor in Kalypsys' series B financing. Heller is an investment advisor for life sciences transactions to One Equity Partners, a JPMorganChase company.


Guava Technologies has appointed David King as vice president of product development. King was previously head of new product development and product integration at Iolon, a privately held manufacturer of tunable optical components. Prior to joining Iolon, King was principal engineer at Agilent Technologies, where he developed in vitro diagnostic testing instrument systems for use in clinical settings, and Hewlett Packard, where he worked on medical devices and nucleic acid array technologies.


Matthew Kalnik has been named senior vice president of business development of Genaissance Pharmaceuticals. Kalnik most recently held the position of executive director and head of pharmacogenomics commercial development operations in the global prescription business at Pharmacia and then Pfizer, following its acquisition of Pharmacia. Genaissance also announced that Krishnan Nandabalan has been promoted to the position of vice president of corporate development, primarily responsible for expanding the firm's HAP technology into new markets and disease areas.


Archemix has appointed Augustine Yee as vice president of business development. Yee comes to Archemix from Prometheus Laboratories, where he was vice president and head of business and corporate development.


Thermo Electron has hired Bill Summers as global sales director of informatics, a newly created position. Summers comes to Thermo from Aspen Technology, where he was most recently vice president of sales for chemicals/pharmaceuticals.


BioWisdom has appointed Susan Lowther as its chief financial officer. Lowther most recently worked as a consultant to early-stage venture capital-backed companies. She previously served as finance director of RiboTargets until its merger with British Biotech in 2003. Lowther has also held senior financial management positions at Lonza Biologics, Celltech Group, and GD Searle (a division of Monsanto). 


Bruce Compton has been appointed vice president and general manager for the chromatography business unit of Eksigent Technologies. He joins Livermore, Calif.-based Eksigent from Thermo Electron, where he was vice president and general manager for chromatography products. Prior to that, he was director of research and development for the chemical division, and later vice president of advanced separation technology, of Waters. Compton received a PhD from McGillUniversity in Canada and a BA in biological sciences from the Universityof Hawaii.


Steffen Nock, co-founder and former vice president of biochemistry of protein chip company Zyomyx, has is now president of Absalus, a therapeutic antibody company based in Mountain View, Calif. He is also a co-founder of QualityProteomics, previously ProMab, also located in Mountain View.


John Flavin has been promoted from CFO to president of Advanced Life Sciences of Woodridge, Ill. Prior to joining ALS, he was COO of MediChem Life Sciences, also of Woodridge. He also served as CEO of MediChem's protein engineering and proteomics subsidiaries, Emerald BioStructures, ThermoGen, and AXAS. Flavin holds an MBA from LewisUniversity in Romeoville, Ill., and a BS in business administration from MarquetteUniversity in Milwaukee.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.